Curevac is acquiring privately held Frame Cancer Therapeutics, which focuses on advanced genomics and bioinformatics to identify both unique and common neoantigens for various cancers. "Embedding Frame's technology and expertise into Curevac's oncology research complements our ability to identify and validate promising neoantigens for our mRNA cancer vaccine programs," emphasized Franz-Werner Haas...